Abstract: An exercise therapy device includes pedals, a pedal rotation shaft connected to the pedals, a load motor for driving the pedal rotation shaft, and a load control device for controlling the load motor to cause rotating motion of the pedal rotation shaft to be started by the load motor.

Abstract: To provide an exercise therapy device capable of highly motivating an exerciser to continue exercise therapy, the exercise therapy device equipped with AV equipment and a rotation shaft includes: a rotation speed detection unit; a display unit for displaying menu items of contents and the content reproduced by the AV equipment; a menu selection unit for sequentially displaying the menu items of contents when the rotation shaft is rotating and, when one of the menu items has been externally selected, confirming the one of the menu items as a menu to be displayed by the AV equipment; and a reproduction speed setting unit for setting a constant or a variable speed. The AV equipment reproduces the content at one of the predetermined constant speed or the variable speed which is set when the rotation shaft is rotating, and stops reproducing the content when the rotation shaft is stopped.

Abstract: An exercise therapy device includes pedals, a pedal rotation shaft connected to the pedals, a load motor for driving the pedal rotation shaft, and a load control device for controlling the load motor to cause rotating motion of the pedal rotation shaft to be started by the load motor.

Abstract: Compounds for treating or preventing cerebrovascular diseases are disclosed. These compounds are 5-HT antagonists. More specifically, these compounds, when combined with pharmaceutically acceptable carriers or excipients and administered to animals including humans, are useful in treating or preventing cerebrovascular dementia.

Abstract: Compounds for treating or preventing cerebrovascular diseases are disclosed. These compounds are 5-HT antagonists. More specifically, these compounds, when combined with pharmaceutically acceptable carriers or excipients and administered to animals including humans, are useful in treating or preventing cerebrovascular dementia.

Abstract: The present invention is drawn to methods for treating cerebral infarction by administering to a patient in need thereof an effective amount of a compound of the formulae (I, II or III): ##STR1##

Abstract: This invention relates to a biologically active WS-7739-A substance and a biologically active WS-7739-B substance which have pharmacological activities and are useful for the treatment of asthma, thrombosis and the alike.

Abstract: N-acylpeptides are disclosed of the formula: ##STR1## wherein R.sup.1 is alkanoyloxy or alkenoyloxy; R.sup.2 is alkyl or alkenyl; R.sup.3 and R.sup.4 are each lower alkyl, hydroxy(lower)alkyl, ar(lower)alkyl, esterified carboxy(lower)alkyl, carboxy(lower)alkyl, protected amino(lower)alkyl or amino(lower)alkyl; R.sup.5 is hydrogen, hydroxy(lower)alkyl, protected amino(lower)alkyl, amino(lower)alkyl, carboxy(lower)alkyl or esterified carboxy(lower)alkyl; R.sup.6 is carboxy, esterified carboxy or sulfo(lower)alkyl; A.sup.1, A.sup.2 and A.sup.3 are each bond or lower alkylene; and m and n are each an integer of 0 or 1; or its pharmaceutically acceptable salt. These compounds have anti-complementary activity and fibrinolytic activity, and are useful as therapeutic agents for immune-complex diseases or autoimmune diseases such as nephritis, rheumatic diseases, systemic lupus erythematosus, etc. and thrombosis such as cerebral apoplexy, coronary insufficiency, pulmonary embolism, etc.

Abstract: This invention relates to new N-acylpeptide compounds of immunological activity, said compounds being of the formula: ##EQU1## wherein R.sup.1 and R.sup.2 are each alkyl or alkenyl;R.sup.3 is hydrogen, lower alkyl, hydroxy(lower)alkyl, heterocyclic(lower)alkyl or ar(lower)alkyl, wherein the aryl moiety may have hydroxy or protected hydroxy;R.sup.4 is carboxy, esterified carboxy, carboxy(lower)alkyl or esterified carboxy(lower)alkyl;X is bond or lower alkylene;Y is lower alkylene or lower alkylidene; andn is an integer of 0 to 1;or its pharmaceutically acceptable salt.

Abstract: A new triazene compound of the formula:R--CH.dbd.N--N.dbd.N--OHwherein R is alkyl, alkenyl or aryl and its pharmaceutically acceptable salts thereof. The production and use of such compounds are also disclosed. The compounds are useful as smooth muscle relaxants and hypotensives.

Abstract: Hyaluronidase obtained from Streptomyces koganeiensis has the following characteristics:(a) Acts as an endo B-hexosaminidase(b) Degrades hyaluronic acid but not chondroitin sulfate A, C, or chondroitin(c) Optimum pH around 4.0(d) Stable pH range 4.0-11.3(e) Optimum temperature around 60.degree. C.(f) Stable a temperature below 60.degree. C.